| 000 | 01642 a2200457 4500 | ||
|---|---|---|---|
| 005 | 20250513215448.0 | ||
| 264 | 0 | _c20010108 | |
| 008 | 200101s 0 0 eng d | ||
| 022 | _a0277-0008 | ||
| 024 | 7 |
_a10.1592/phco.20.11.950.35261 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aBrophy, D F | |
| 245 | 0 | 0 |
_aCost-effectiveness of sevelamer versus calcium carbonate plus atorvastatin to reduce LDL in patients with chronic renal insufficiency with dyslipidemia and hyperphosphatemia. _h[electronic resource] |
| 260 |
_bPharmacotherapy _cAug 2000 |
||
| 300 |
_a950-7 p. _bdigital |
||
| 500 | _aPublication Type: Comparative Study; Journal Article | ||
| 650 | 0 | 4 | _aAtorvastatin |
| 650 | 0 | 4 |
_aCalcium Carbonate _xeconomics |
| 650 | 0 | 4 | _aCost-Benefit Analysis |
| 650 | 0 | 4 | _aDecision Support Techniques |
| 650 | 0 | 4 |
_aEpoxy Compounds _xeconomics |
| 650 | 0 | 4 | _aHealth Care Costs |
| 650 | 0 | 4 |
_aHeptanoic Acids _xeconomics |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aHydroxymethylglutaryl-CoA Reductase Inhibitors _xeconomics |
| 650 | 0 | 4 |
_aHyperlipidemias _xblood |
| 650 | 0 | 4 |
_aHypolipidemic Agents _xeconomics |
| 650 | 0 | 4 |
_aKidney Failure, Chronic _xblood |
| 650 | 0 | 4 |
_aLipoproteins, LDL _xblood |
| 650 | 0 | 4 |
_aPhosphates _xblood |
| 650 | 0 | 4 | _aPolyamines |
| 650 | 0 | 4 |
_aPolyethylenes _xeconomics |
| 650 | 0 | 4 |
_aPyrroles _xeconomics |
| 650 | 0 | 4 | _aSevelamer |
| 700 | 1 | _aWallace, J F | |
| 700 | 1 | _aKennedy, D T | |
| 700 | 1 | _aGehr, T W | |
| 700 | 1 | _aHoldford, D A | |
| 773 | 0 |
_tPharmacotherapy _gvol. 20 _gno. 8 _gp. 950-7 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1592/phco.20.11.950.35261 _zAvailable from publisher's website |
| 999 |
_c10888406 _d10888406 |
||